menu
    • menu
    [{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw | Universitaire Ziekenhuizen KU Leuven","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sulfadiazine","moa":"Bacterial dihydropteroate synthase","graph1":"Oncology","graph2":"Phase III","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw | Universitaire Ziekenhuizen KU Leuven","highestDevelopmentStatusID":"10","companyTruncated":"Radboud University Medical Center \/ ZonMw | Universitaire Ziekenhuizen KU Leuven"}]

    Find Clinical Drug Pipeline Developments & Deals for Sulfadiazine

    Menu

    Sulfadiazine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Radboud University Medical Center

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Radboud University Medical Center

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulfadiazine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : ZonMw | Universitaire Ziekenhuizen KU Leuven

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Perioperative SDD to Prevent Infectious Complications After Esophagectomy

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 19, 2023

                            Lead Product(s) : Sulfadiazine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : ZonMw | Universitaire Ziekenhuizen KU Leuven

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The George Institute

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            The George Institute

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulfadiazine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Imperial College London | Sunnybrook Health Sciences Centre

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 17, 2015

                            Lead Product(s) : Sulfadiazine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Imperial College London | Sunnybrook Health Sciences Centre

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth